MetaVia以810万美元的承销公开募股价格

2026-01-15 22:55

MetaVia (NASDAQ:MTVA) on Thursday stated that it priced an underwritten public offering of common stock and Series C and D warrants for gross proceeds of about $8.1M, with underwriters granted a 45-day option to purchase up to an additional 0.39M common shares, 0.59M Series C warrants, and 0.59 Series D warrants.
The offering consists of 2.61M common shares, 3.92M Series C warrants, and 3.92M Series D warrants at a combined price of $3.10 per share.
Series C warrants are immediately exercisable at $3.10, expiring in five years, and Series D warrants at $3.10, expiring in two years.
Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager in connection with the underwritten public offering.
Full exercise of pre-funded Series C and D warrants could yield up to $24M in gross proceeds.
Proceeds will fund working capital, corporate purposes, and the clinical development of DA-1726 obesity trials.
The offering is expected to close on or about Jan. 16, 2026, subject to customary conditions.
Shares -41.88%.

More on MetaVia